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Genotype # Adiposity Interaction Linkage Analyses Reveal
a Locus on Chromosome 1 for Lipoprotein-Associated
Phospholipase A2, a Marker of Inflammation and Oxidative Stress
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Matthew P. Johnson, Jeremy B. M. Jowett, Thomas D. Dyer, Jeff T. Williams, Eric K. Moses,
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Because obesity leads to a state of chronic, low-grade inflammation and oxidative stress, we hypothesized that the
contribution of genes to variation in a biomarker of these two processes may be influenced by the degree of adiposity.
We tested this hypothesis using samples from the San Antonio Family Heart Study that were assayed for activity of
lipoprotein-associated phospholipase A2 (Lp-PLA2), a marker of inflammation and oxidative stress. Using an approach to
model discrete ( ) interaction, we assigned individuals to one of two discrete diagnosticgenotype# environment G# E
states (or “adiposity environments”): nonobese or obese, according to criteria suggested by the World Health Organization.
We found a genomewide maximum LOD of 3.39 at 153 cM on chromosome 1 for Lp-PLA2. Significant interactionG# E
for Lp-PLA2 at the genomewide maximum ( ) was also found. Microarray gene-expression data were
54Pp 1.16# 10
analyzed within the 1-LOD interval of the linkage signal on chromosome 1. We found two transcripts—namely, for Fc
gamma receptor IIA and heat-shock protein (70 kDa)—that were significantly associated with Lp-PLA2 ( for both)P ! .001
and showed evidence of cis-regulation with nominal LOD scores of 2.75 and 13.82, respectively. It would seem that there
is a significant genetic response to the adiposity environment in this marker of inflammation and oxidative stress.
Additionally, we conclude that interaction analyses can improve our ability to identify and localize quantitative-G# E
trait loci.
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From studies of humans and animal models, accumulating
evidence has suggested a positive association between mea-
sures of adiposity and biomarkers of inflammation and
oxidative stress.1–11 At the molecular level, this association
seems to arise from the increased expression of adipokines
in the white adipose tissue1,2 of central adipose depots.3–5
As a result of these advances, a unifying theory on the
etiology of the metabolic syndrome posits that obesity
leads to a state of chronic, low-grade inflammation and
oxidative stress and that it is this pathological condition—
of chronic inflammation and oxidative stress—that un-
derlies most of the clinical sequelae associated with the
metabolic syndrome.12–27
On the basis of these findings, we hypothesized that the
contribution of genes to variation in biomarkers of in-
flammation and oxidative stress may be influenced by the
degree of adiposity—that is, “adiposity environment”—in
individuals in whom they are expressed. We sought to test
this hypothesis in the San Antonio Family Heart Study
(SAFHS), which is a study of the genetic determinants of
cardiovascular disease (CVD) in Mexican American fam-
ilies of San Antonio. We used the modeling approach
of discrete ( ) interaction,genotype# environment G# E
where two discrete adiposity environments—obese and
nonobese—were defined according to criteria suggested by
the World Health Organization (WHO).28
The SAFHS population comprises large Mexican Amer-
ican extended families randomly ascertained with respect
to CVD.29 The SAFHS protocols were approved by the In-
stitutional Review Board at the University of Texas Health
Science Center at San Antonio, and all study participants
provided written informed consent. The pedigree relation-
ships exhibited by the sample population are reported in
table 1.
Fasting blood samples were obtained from study partic-
ipants at a clinic exam and were shipped the same day to
Southwest Foundation for Biomedical Research (SFBR), San
Antonio. Plasma and serum were isolated by low-speed
centrifugation, and the buffy coat was harvested for DNA
extraction.
We analyzed a biomarker of inflammation and oxidative
stress in atherogenesis—namely, plasma activity of lipo-
protein-associated phospholipase A2 (Lp-PLA2), which is
also known as “platelet-activating factor acetylhydrolase”
(PAF-AH).30–32 Plasma Lp-PLA2 activity was determined us-
ing a commercial colorimetric assay (Cayman Chemical)
with 2-thio-PAF as substrate and according to the manu-
facturer’s directions. Samples were run in duplicate, with
average coefficients of variation of 2.5%. Enzyme activity
was expressed in units of mmol/min/ml. Residuals from a
least-squares multiple linear regression—with use of age,
sex, age squared, oral-contraceptive use, and menopause
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Figure 1. Lp-PLA2 linkage on chromosome 1. Comparison of the
interaction model under the WHO definition of adiposityG# A
status with the standard linkage model. The solid line indicates
LOD plot under the interaction model and the dashed lineG# A
indicates LOD plot under the standard linkage model.
status as independent variables—were exactly normalized
using an inverse Gaussian transformation in SOLAR (here-
after referred to as “rnLp-PLA2”).
33 Anthropometrics, in-
cluding height, weight, and waist and hip circumferences,
were measured at a clinic exam as part of the SAFHS pro-
tocol. BMI, defined as the ratio of weight (kg) to height
squared (m2), and waist-to-hip ratio (WHR), defined as the
ratio of waist circumference to hip circumference, were
determined from the anthropometric data.
It is by now well established that abdominal obesity is
a major metabolic-syndrome risk factor.19,22,24,27 In an at-
tempt to incorporate the abdominal-obesity component
into a clinical definition of the metabolic syndrome, a
WHO expert committee defined the abdominally obese as
those with a combined BMI 130 and a WHR2kg#m
10.90 in men and 10.85 in women.28 We used these cutoffs
to define a dichotomous adiposity environment, as given
by the indicator variable
1 if obese
f p .• {0 if nonobese
The sample size of individuals with data for rnLp-PLA2,
BMI, and WHR combined is 1,341.
DNA extracted from lymphocytes was used in PCRs for
the amplification of individual DNA ( ) at 432Np 1,339
dinucleotide-repeat microsatellite loci (i.e., STRs), spaced
∼10 cM apart across the 22 autosomes, with fluorescently
labeled primers from the MapPairs Human Screening set,
versions 6 and 8 (Research Genetics). PCRs were performed
separately, according to manufacturer specifications, in
Applied Biosystems 9700 thermocyclers. The products of
separate PCRs, for each individual, were pooled using the
Robbins Hydra-96 Microdispenser, and a labeled size stan-
dard was added to each pool. The pooled PCR products
were loaded into an ABI PRISM 377 or 3100 Genetic An-
alyzer for laser-based automated genotyping. The STRs and
standards were detected and quantified, and genotypes
were scored using the Genotyper software package (Ap-
plied Biosystems).
Mistyping analyses were performed on the preliminary
genotype-marker data with SimWalk2, following the rec-
ommendations of the program developers for accounting
for mistyping error, by (1) blanking the errant called al-
leles, (2) recalling them conditional on the analysis (i.e.,
reassigning them under a different allele designation), or
(3) retyping the mistyped marker or markers as resources
permitted.34,35 Our overall rate of blanking mistyped mark-
ers was 1.37%. These mistyping analyses allow investi-
gators to account for Mendelian errors and spurious dou-
ble recombinants, both of which can severely reduce the
power of a linkage analysis if not accounted for.35 After
addressing mistyping errors (by blanking, recalling, or re-
typing), these genotype data were then used to compute
maximum-likelihood estimates of allele frequencies in SO-
LAR.33 Empirical estimates of identity-by-descent (IBD) al-
lele sharing at points throughout the genome for every
relative pair were computed using the Loki package, which
uses Markov chain–Monte Carlo methods.36 The multi-
point IBD estimates are required under our variance-com-
ponents modeling approach (see below). The SimWalk2
and Loki programs both require chromosomal maps. We
used the set of high-resolution chromosomal maps pro-
vided by the research group at deCODE genetics, which
are included in Web table E in the work of Kong et al.37
Total RNA was extracted from 1,000 lymphocyte sam-
ples by use of QIAGEN RNeasy 96 kits, and concentration
was determined spectrophotometrically by use of a Nano-
Drop. Integrity of resuspended total RNA was determined
by electrophoretic separation and subsequent laser-in-
duced florescence detection by use of the RNA 6000 Nano
Assay Chip Kit on the Bioanalyzer 2100 with the 2100
Expert software (Agilent Technologies). Antisense RNA
(aRNA) was synthesized and purified using the Ambion
MessageAmp II Amplification Kit, following the Illumina
Sentrix Array Matrix 96-well expression protocol. Biotin-
16-UTP (Roche)–labeled aRNA was hybridized to Illumina
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Figure 2. Multipoint genome scan of Lp-PLA2
Sentrix Human Whole Genome (WG-6) Expression Bead-
Chips. These BeadChips contain six arrays, each with
47,289 probes derived from human genes in the National
Center for Bioinformatics Information (NCBI) Reference
Sequence and UniGene databases. This system uses a “di-
rect hybridization” assay, whereby gene-specific probes are
used to detect labeled RNAs. Each bead in the array con-
tains a 50-mer, sequence-specific oligonucleotide probe
synthesized using Illumina’s Oligator in-house technol-
ogy. Each array on a Human WG-6 BeadChip provides
genomewide transcriptional coverage of well-character-
ized genes, gene candidates, and splice variants. The Hu-
man WG-6 Expression BeadChips were scanned on the
Illumina BeadArray 500GX Reader, a two-channel, 0.8-
mm–resolution confocal laser scanner, by use of Illumina
BeadScan image data acquisition software (ver. 2.3.0.13).
Illumina BeadStudio software (ver. 1.5.0.34) was used for
data visualization and quality-control metrics.
To preclude confusion, we note that these data are ex-
pression levels of RNA transcripts and are not genotypic
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Figure 3. interaction effects. The solid line with unblack-G# A
ened diamonds indicates genetic SD (gsd), the solid line with
blackened circles indicates QTL SD (qsd), and the dashed line with
blackened triangles indicates environmental SD (esd).
data. They are treated herein as phenotypic data. It should
also be noted that lymphocytes may not fully reflect the
expression of all genes influencing adiposity, oxidative
stress, and inflammation. However, there is growing use
of lymphocytes as surrogate models for other tissues, such
as neural tissues,38–40 and such work has generated substan-
tial new discoveries.40
The hypothesis of differential response to two environ-
ments is an example of the application of the theory of
discrete interaction.41 There is now a good numberG# E
of published reports on the utility of this approach, both
for understanding the relationship between genotype and
environment in the process of phenotype determination
and to aid in the identification and localization of QTLs.42–
56 Under the theory of discrete interaction, signif-G# E
icant interaction arises for heterogeneity in the additive
genetic variance (polygenic or QTL), an additive genetic
correlation coefficient (polygenic or QTL) significantly dif-
ferent from unity, or both conditions.41 Therefore, to test
for interaction, we sought to falsify the null versionsG# E
of the conditions that give rise to interaction, whichG# E
are a homogeneous additive genetic variance (polygenic
or QTL) and/or an additive genetic correlation coefficient
(polygenic or QTL) equal to 1.
For all possible pairwise combinations of values for the
adiposity indicator variables and , where x and z aref fx z
index individuals in the sample, the envi-G# adiposity
ronment ( ) interaction model covers three types ofG#A
pairwise comparisons: within-obese, within-nonobese, and
across-adiposity-environment comparisons:
Cov(y ,y )x z
2 2 2ˆ2f j f j  d j ;xz go xz qo xz eo
G f p f p 1x z
2 2 2ˆ2f j f j  d j ;xz gn xz qn xz enp , (1)
G f p f p 0x z
ˆ{2f j j r f j j r ;xz go gn G o,n xz qo qn Q o,n( ) ( )
G f p 1,f p 0, or f p 0,f p 1x z x z
where is any given phenotype; gives the expectedy 2fxz
coefficient of relationship,
1 k1j
f p E ,xz ( )[ ]2 2 k2j
where the kij are coefficients giving the jth locus-specific
probability that a pair of relatives share i alleles IBD; ˆfxz
is the estimated kinship coefficient based on marker data;
is defined as 1 when individuals x and z are the samedxz
and 0 otherwise; , , , , , and are, respectively,2 2 2 2 2 2j j j j j jgo gn qo qn eo en
the within-obese and within-nonobese additive polygenic,
QTL, and environmental variances (the positive square
roots of which give their corresponding SDs); and rG(o,n)
and are the across-adiposity–environment additiverQ(o,n)
polygenic and QTL correlation coefficients, respectively.
We refer to this model as the “linkage interaction model.”
It will be necessary at this point to define the polygenic
interaction model as a constrained version of the linkage
interaction model in which the following constraint holds:
.2 2j p j p 0qo qn
The top and middle cases on the right side of the pre-
vious equation are the within-adiposity–environment ver-
sions of the standard linkage model used by Almasy and
Blangero,33 which hold for the obese and nonobese en-
vironments, respectively. The crucial part of the model is
given by the bottommost case, which gives the covariance
for the across-adiposity–environment comparison. Note
that we are allowing for the possibility of heterogeneity
in the residual environmental variance. This is necessary
to preclude bias in detection of heterogeneity in the ge-
netic-variance components. In all of our models, wasrQ(o,n)
constrained to equal 1, because the contribution to the
model made by tends to be offset by the increase inrQ(o,n)
degrees of freedom relative to the standard linkage model
(results not shown).
We used SOLAR to perform genome screens under stan-
dard linkage and interaction models across all 22G#A
autosomes. For the standard linkage case, the likelihood
ratio statistic, denoted by , is distributed as .571 12 2L x  x0 12 2
It is important to note that SOLAR automatically corrects
the LOD score for the standard case, to account for the
above mixture distribution. The observed LOD scores un-
der the interaction model need to be further cor-G#A
rected because of the increase in degrees of freedom rel-
ative to the standard linkage model. Following Self and
Liang,57 it can be shown that when the polygenic inter-
action and linkage interaction models are compared, isL
distributed as . We refer to this latter cor-1 1 12 2 2x  x  x0 1 24 2 4
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CTMP C-terminal modulator protein Protein kinase B regulation 147.18 .00174 .04653
CTSS Cathepsin S Elastase activity 147.64 45.15# 10 .01738
SNX27 Sorting nexin, family member 27 Intracellular sorting 148.52 44.81# 10 .01738
FLJ23221 Chromosome 1 ORF 54 ORF 148.78 .00164 .04653
PBXIP1 Pre-B-cell leukemia transcription factor interacting protein 1 Transcriptional regulation 151.85 42.77# 10 .01738
SYT11 Synaptotagmin, isoform 11 Mast-cell regulation 152.77 41.30# 10 .01738
FCER1A Fc epsilon receptor 1A Mast-cell activation 156.21 43.03# 10 .01738
Hmm8932 Hmm8932 Gnomon predicted gene 157.95 45.21# 10 .01738
FCGR2A Fc gamma receptor 2A C-reactive–protein receptor 158.42 41.52# 10 .01738
HSPA6pHSP70 Heat-shock protein (70 kDa) Chaperone-protein folding 158.44 44.18# 10 .01738
a Locations are averaged interpolations against our map, with use of physical distances obtained from the University of California–Santa Cruz (UCSC)
genome browser (Human [Homo sapiens] Genome Browser Gateway) for the two markers flanking the linkage peak at 153 cM.
b P value of the beta coefficient for Lp-PLA2 in a linear model in which the transcript is the dependent variable.
rection for increase in degrees of freedom as the corrected
LOD score. Since the LOD score is equal to , we canL2ln(10)
obtain a corrected LOD score on the basis of the appro-
priate distribution. To test the null hypothesis of homo-
geneity in the QTL variance (i.e., ) at the genome-2 2j p jqo qn
wide maximum (the point along the genome that has the
highest LOD score), we performed likelihood-ratio tests.
For model comparisons in which the QTL variances are
constrained to be equal under the null hypothesis and in
which the QTL variances are free to vary under the alter-
native hypothesis, is distributed as .2L x1
We found that rnLp-PLA2 has a heritability of 0.55
( ). Using the interaction model, we41Pp 2.07# 10 G#A
found a corrected, genomewide maximum LOD of 3.39
at 153 cM on chromosome 1 near marker D1S1595 (figs.
1 and 2). A LOD score of 3.0 is taken as indicative of
genomewide significance.58 Moreover, using an approach
based on the work of Feingold et al.59 and implemented
in Gauss 6.0.17 (Aptech Systems), we can compute the
genomewide P value that corresponds to our LOD score
of 3.39. This approach takes into account the finite marker
density in the linkage map used in the multipoint QTL
screens and the mean recombination rate for the pedi-
greed population studied. The genomewide P value com-
puted under said approach is .01477. In contrast, max-
imization of models lacking interaction did notG#A
provide strong evidence of a QTL anywhere in the genome.
There is, however, a suggestive LOD score of 2.46 at 140
cM on chromosome 1 under the standard linkage model,
with a corresponding genomewide P value of .14402. To
highlight the improvement given by the incorporation of
interaction effects, the results under the standard link-
age model for chromosome 1 are also displayed. It will be
noted that the location of the maximum LOD score
changes from 140 cM on chromosome 1 under the stan-
dard linkage model to 153 cM on chromosome 1 under
the interaction model. One plausible explanationG#A
is that the shift in peaks is simply the result of a model
that affords a more precise signal location. In keeping with
this view, Blangero et al. showed that interactionG# E
models increase the power to detect linkage signals and
precision of signal location.60 Another plausible explana-
tion is that there is another gene located at the linkage
peak under the standard linkage model and that the
interaction model recovers information that, in theG#A
aggregate, points to another location, harboring another
gene, as the maximum while at the same time retaining
the peak first observed under the standard linkage model.
We cannot distinguish between these alternatives at the
present time.
We found significant QTL interaction for rnLp-G#A
PLA2 at the genomewide maximum on chromosome 1
( ) (fig. 3). Specifically, the QTL additive4Pp 2.32# 10
genetic variance decreased from the nonobese to the obese
environment. This finding may indicate a gene that is
negatively regulated by adipose tissue. For instance, adi-
ponectin is negatively associated with obesity,61,62 and a
regulatory protein that both is related to the adiponectin
gene and is itself negatively regulated by the proinflamma-
tory cytokine, tumor necrosis factor-a (TNF-a), has been
shown to be located in a region encompassing our linkage
signal.63–65 Additionally, the gene for the adiponectin re-
ceptor AdipoR1 has been mapped to a broad region on
chromosome 1 that encompasses our linkage signal.66 In-
terestingly, the polygenic additive genetic variance exhib-
ited significant heterogeneity (i.e., polygenic inter-G#A
action) ( ) (fig. 3) and increased from the4Pp 3.54# 10
nonobese to the obese environment. This observation is
consistent with the knowledge that adiposity promotes
the expression of proinflammatory cytokines, such as
TNF-a.12–27 Our findings of decreasing QTL variance and
increasing polygenic variance in response to the adiposity
environment may be reflective of down-regulated and up-
regulated signals related to the inflammation response.
The additive environmental variance also significantly de-
creased from the nonobese to the obese environment
( ) (fig. 3). This observation is consistent4Pp 6.86# 10
with the way the determinative system affecting Lp-PLA2
comes under relatively more genetic control when going
from the nonobese to obese environment.
To our knowledge, there are at least three other genome-
scan studies that have reported signals on chromosome 1
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Figure 4. Transcripts under the linkage signal; transcripts within
the 1-LOD interval of the linkage peak at 153 cM. Top, Negative
logarithm (base 10) of the Q values for the test of association
between the transcript and Lp-PLA2 plotted against chromosomal
location. The dashed line corresponds to the Q value threshold of
.05 for the beta coefficients. Bottom, Negative logarithm (base
10) of the Q values computed from the pointwise LOD scores plotted
against chromosomal location. The grid line at 2.0 corresponds to
the Q value threshold of .01 for the pointwise LOD scores. Location
is expressed in terms of megabases along the ordinate, for better
separation. To plot all values on a scale at which the Q value
threshold could be easily discerned, the three highest log Q
values for MGC31963, HSP70, and ATF6 were arbitrarily given a
log Q value of 3.0. Their real corresponding Q values are in table
3 (HSPA6pHSP70).
in the vicinity of our signals for traits related to obesity
and/or the metabolic syndrome.67–69 Ng et al.,67 in the
Hong Kong Family Diabetes Study, reported their genome-
wide maximum LOD of 4.5 at chromosome 1q near
marker D1S1653 for the metabolic syndrome. Marker
D1S1653 is located at 151.68 cM on the deCODE map and
is very near our genomewide maximum for the G#A
interaction analyses. In the Framingham Heart Study,68
Dupuis et al. reported a LOD of 3.86 at chromosome 1q
near marker D1S1679 for monocyte-chemoattractant pro-
tein-1 (MCP-1). Marker D1S1679 is positioned at 160 cM
in our chromosome 1 map, which is just at the outer mar-
gin of the 1-LOD interval in our interaction an-G#A
alyses. Moreover, similar to Lp-PLA2, MCP-1 is another
biomarker of vascular inflammation. In a study of nuclear
families ascertained at the University of Pennsylvania,69
Reed et al. reported a LOD equivalent of 2.2 on chro-
mosome 1 near marker D1S484 for plasma cholesterol lev-
els. Marker D1S484 is at 157.51 cM on the deCODE map,
which again is within the 1-LOD interval in our G#A
interaction analyses.
We analyzed the gene-expression data to further char-
acterize the area under the linkage peak. Because there are
exactly 341 transcripts within the 1-LOD interval around
the maximum, we employed a statistical methodology,
based on the false-discovery rate (FDR) and Q Value con-
cepts, to deal with the multiple-testing problem.70–74 The
literature on the detection of differential gene expression
in DNA microarray data—and similar such cases of data
mining in statistical genetics and genomics—seems to
point to methods that control the FDR rather than to the
highly conservative method of controlling for the fami-
lywise error rate, such as the well-known Bonferroni cor-
rection.70–81 The Q value is mathematically defined as the
minimum positive FDR (pFDR) observed for a set of sig-
nificant results: . It is a measure ofQ valuepmin{pFDR}
the proportion of false-positive results expected on de-
claring a particular test to be significant at a given signif-
icance level, denoted by a. Following the recommenda-
tions of the developers of this method for preliminary
investigations, we can threshold on the Q value, such that
we obtain an .FDR a
In linear models in which the transcript is the depen-
dent variable and rnLp-PLA2 is the covariate, we can use
the P value on the beta-coefficient for rnLp-PLA2 as a mea-
sure of the association of the transcript with rnLp-PLA2.
By the Q Value method, we observed 10 transcripts under
the Q value threshold for (table 2 and fig.FDR a .05
4). To test for cis-regulation, which is defined as regulatory
elements located at the gene,82–84 we computed the point-
wise LOD score at the location reported in the NCBI and
UniGene databases for each of the 341 transcripts within
the 1-LOD interval of the rnLp-PLA2 linkage signal. We
take as our significance level a LOD score of 1.44, which
is equivalent to . Using the Q Value method for Pa .01
values computed from the LOD scores, and thresholding
for , we observed seven transcripts (table 3FDR a .01
and fig. 4). Two of these—namely, the gene encoding
Fc gamma receptor IIA (FCGR2A [MIM 146790]) (LOD
2.75) and the gene encoding heat-shock protein (70 kDa)
(HSP70) (LOD 13.82) (HSP70pHSPA6 [MIM 140555])—are
presented in tables 2 and 3. We interpret these results
to mean that these two genes—namely, FCGR2A and
HSP70—are good candidates to pursue for further study.
FCGR2A is the receptor for C-reactive protein (CRP), a
well-known acute-phase protein of the inflammation pro-
cess involved in vascular dysfunction.85–87 Immunocyto-
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ARNT Aryl hydrocarbon receptor nuclear translocator Xenobiotic metabolism 147.72 58.46# 10 .00421
MGC31963 Chromosome 1 ORF 85 ORF 153.20 194.75# 10 0
FCRH3 Fc receptor–like protein 3 Immunoglobulin receptor 154.59 52.98# 10 .00178
FCGR2A Fc gamma receptor 2A C-reactive–protein
receptor
158.42 .00019 .00693
HSPA6pHSP70 Heat-shock protein (70 kDa) Chaperone-protein folding 158.44 167.52# 10 0
FCGR2B Fc fragment of immunoglobulin Mast-cell activation 158.49 52.23# 10 .00167
ATF6 Activating transcription factor 6 Transcription factor 158.60 113.41# 10 0
a Locations are averaged interpolations against our map, with use of physical distances obtained from the UCSC genome browser
(Human [Homo sapiens] Genome Browser Gateway) for the two markers flanking the linkage peak at 153 cM.
b P values are computed from the nominal LOD score at the location given in the NCBI and UniGene databases.
chemical work has shown that FCGR2A is highly expressed
in the proliferative zones of atherosclerotic lesions.88 More-
over, it has been shown in human monocytes that have
the H131 mutation at the FCGR2A gene that FCGR2A has
a significantly decreased binding to CRP87 and that this
mutation seems to confer protection against peripheral
atherosclerosis.89 The increased expression of heat-shock
proteins, including HSP70, is known to be associated with
an induced inflammatory response.90–93 Consistent with
this knowledge, it has been noted that HSP70 is overex-
pressed in several cell types, including monocytes, mac-
rophages, and smooth-muscle cells, in advanced athero-
sclerotic lesions.93
It should be noted that the beta-coefficients indicating
the relationship of the transcript to rnLp-PLA2 were nega-
tive in sign for both transcripts (for FCGR2A, ;bp0.13
for HSP70, ). This is consistent with our obser-bp0.12
vation of a decreasing QTL variance in rnLp-PLA2 from
the nonobese to the obese-adiposity environment. To fur-
ther characterize these transcripts, we performed multiple
linear-regression analyses of the transcript expression lev-
els as the independent variable and of age, sex, their sec-
ond-order terms, and a relevant clinical trait as the de-
pendent predictors. The analyzed clinical traits were dia-
betes status, impaired glucose tolerance, insulin resistance,
adiposity status as defined above, dyslipidemia status, hy-
pertension status, history of heart attack, history of heart
surgery, and common and internal carotid artery intima-
media thicknesses. For definitions of diabetes status, im-
paired glucose tolerance, insulin resistance, dyslipidemia
status, and hypertension status, we again referred to the
criteria suggested by the WHO.28 There were significant
associations between FCGR2A-expression levels and adi-
posity status ( ), insulin resistance ( ),Pp .01636 Pp .00255
and dyslipidemia status ( ). There was one5Pp 1.3# 10
clearly significant association between HSP70-expression
levels and dyslipidemia status ( ). The associa-Pp .02578
tion between HSP70-expression levels and insulin resis-
tance was barely nonsignificant ( ). All otherPp .05613
associations for both transcripts were nonsignificant.
Taken together, the linkage and gene expression analyses
indicate that we have identified a gene that is involved in
the inflammation process and is negatively regulated by
the adiposity environment.
It is notable that, more than a decade ago, Despre´s and
colleagues proposed a hypothesis similar to the one ad-
dressed herein.94–96 It was suggested that visceral adiposity
was capable of modulating the genetic susceptibility to
coronary heart disease. Our results are supportive of that
original hypothesis. In particular, we conclude that there
is a significant polygenic and QTL genetic response to the
adiposity environment in Lp-PLA2, which is an important
biomarker of inflammation and oxidative stress; that G#
interaction analyses can improve our ability to identifyE
and localize QTLs; and that there are at least two strong
candidate genes underlying the QTL that we identified.
Identification of genes and their variants involved in the
inflammatory and oxidative processes in the metabolic
syndrome is of high significance not only for the under-
standing of its metabolic pathogenesis but also for the
development of therapeutic strategies to reduce the mor-
tality and morbidity of this 21st-century epidemic.
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